A clinical research of the Kanghuxin solution combined with alprostadil injection for diabetic foot treatment
Keywords:
Kangfuxin solution, alprostadil injection, diabetic foot (DF), clinical researchAbstract
Objective To observe and analyze the therapeutic effects of Kanghuxin solution combined with injection for diabetic foot treatment.Methods: In present study, 64 patients were divided into control group and treatment group. And the condition of limbs was analyzed according to the skin temperature, arteriopalmus of dorsalis pedis artery index, ankle brachial index, inflammatory factor index in serum. Results: After treatment, the skin temperature in treatment group and control group respectively increased before treatment; PI in treatment group and control group respectively increased before treatment; ABI in treatment group and control group respectively increased before treatment; VPT in treatment group decreased and in control treatment decreased before treatment. After treatment, the number of III level and IV level patients classified by the Wagner classification grading in treatment group was less; the number of III level and IV level patients in treatment group after treatment was also less. And the levels of IL-6, TNF-α and hs-CRP were decreased in two groups after treatment, but the levels of IL-6, TNF-α and hs-CRP in treatment group were lower. Besides, the average hospitalization time of patients was 25.38 ± 7.06 days and average total expense was 9738.47 ± 1025.43; and in control group, average hospitalization time of patients was 30.38 ± 7.24 days and average total expense was 11530.65 ± 1038.57. And these differences had the statistical significance. Conclusion: Kangfuxin solution combined with alprostadil injection treatment was a novel, effective and economic method for DF treatment combining Chinese traditional medicine with Western medicine, which provided innovated ideas for DF medicine treatment.
Published
Data Availability Statement
The analyzed data sets generated during the study are available from the corresponding author on reasonable request.Issue
Section
License
Copyright (c) 2020 The Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.